The DARPA-PS-25-34 "Medics Autonomously Stopping Hemorrhage (MASH)" program solicitation requires abstract submissions for potential invitations to Orals. This document outlines the mandatory abstract template, emphasizing a six-page limit (excluding title page, references, and estimated cost). Abstracts must be UNCLASSIFIED, written in English, and follow specific formatting guidelines for 8-1/2 by 11-inch paper, 1-inch margins, and 12-point font. Key sections include Proposed Approach, Technology Challenges, and Technical Ability. Submissions are to be made via DARPA's Broad Agency Announcement Tool (BAAT), not Grants.gov. The cover sheet requires organizational, technical, and administrative contact information, estimated costs, and a declaration regarding SETA/A&AS services to DARPA. An optional infographic can depict the proposed technology's form factor. The Proposed Approach section should detail robotic hardware, algorithms, training, and integration. Technology Challenges should identify risks and quantify AI/ML training needs. Technical Ability should demonstrate the team's qualifications and past experience. An estimated cost breakdown is also required. Proprietary information must be clearly marked.

The DARPA-PS-25-34 Medics Autonomously Stopping Hemorrhage (MASH) program solicits abstracts for a new initiative. Submissions must adhere to a strict template, be unclassified, and identify proprietary information. Abstracts are limited to six pages, excluding the title page, references, estimated cost, and attachments. The abstract must detail the proposed technical approach, technology challenges, team's technical ability, and estimated costs, including labor, materials, and other direct costs, broken down by functional area and phase. An optional infographic can depict the proposed technology's form factor. This solicitation emphasizes addressing hemorrhage with autonomous medical technologies, integrating with existing platforms, and outlining business strategies for successful prototypes.

The provided government file outlines requirements for detailing robotic platforms, likely for a federal grant or RFP. It instructs performers to describe their robotic platform's FDA indication, system elements, sensor/perception/localization strategies, locomotion/task planning, learning paradigms/training, and animal/synthetic models. The document emphasizes providing specific details for each component, noting that "TBD" should be used for unknown information and multiple rows for significantly different approaches. This structure ensures a comprehensive overview of the proposed robotic system, facilitating evaluation in a proposal context.

The provided document lists various solid organs and arteries, detailing specific anatomical components such as the lobes of the liver, the spleen, pancreas sections, kidneys, and numerous arteries including the abdominal aorta, celiac trunk, mesenteric arteries, renal arteries, and iliac arteries. The document systematically categorizes these anatomical structures, first by type (solid organ or artery) and then by their specific names. This comprehensive list suggests its purpose could be for medical imaging, surgical planning, anatomical study, or as a reference for healthcare-related RFPs, grants, or procurements involving detailed anatomical knowledge or medical equipment specifications.

This DARPA guidance outlines the process for submitting an Oral Presentation Package (OPP) for the MASH program, emphasizing that instructions in the formal invitation take precedence. After abstract review, selected proposers will be invited to submit an OPP, including a title page with specific compliance statements, an oral presentation addressing facilities, technical approach, risks, and transition plans, and examples of past performance. Proposers must also complete a Model Other Transaction (OT) for Prototype Agreement (Attachment A), a DARPA Cost Spreadsheet (Attachment C), and a Technical Clarification Document (TCD) with a risk assessment matrix. OPPs will be evaluated based on technical approach, relevant qualifications, contribution and relevance to DARPA's mission, and budget, with selectability determined by weighing positive and negative aspects against these criteria. Successful OPPs may lead to an OT for Prototype award with fixed, payable milestones for Phases I and II.

Amendment 1 to DARPA-PS-25-34, concerning the Medics Autonomously Stopping Hemorrhage (MASH) Program Solicitation, clarifies that all proposal abstract submissions must include Attachments A-C. This requirement mirrors the guidance provided in Section 4.1 of the original solicitation, with further details available in Attachment A. The amendment's purpose is to ensure clarity and consistency in the submission process for this federal government program.

DARPA's Medics Autonomously Stopping Hemorrhage (MASH) program is soliciting proposals to develop autonomous systems for stabilizing torso hemorrhage in combat casualties. The goal is to detect, localize, and stop life-threatening internal bleeding without a surgeon, providing 48+ hours for evacuation to definitive care. The 36-month program is divided into two phases: Phase I focuses on bleed detection, localization, and end-effector positioning, while Phase II emphasizes full autonomous hemorrhage control and the development of a portable prototype design. The program will award approximately $32.4 million through Other Transaction for Prototype agreements. Proposed solutions must leverage existing robotic platforms and surgical end effectors, achieve high accuracy in bleed detection and localization, and demonstrate the ability to stop bleeding within one hour, limiting blood loss to under 30% of total volume for 48 hours. Human subjects research, manual surgical techniques by medics, and pharmacological solutions as the sole means of hemostasis are not of interest.